206 related articles for article (PubMed ID: 34230200)
1. Imaging Evaluation of Plexiform Neurofibromas in Neurofibromatosis Type 1: A Survey-Based Assessment.
Ahlawat S; Ly KI; Fayad LM; Fisher MJ; Lessing AJ; Berg DJ; Salamon JM; Mautner VF; Babovic-Vuksanovic D; Dombi E; Harris G; Plotkin SR; Blakeley J;
Neurology; 2021 Aug; 97(7 Suppl 1):S111-S119. PubMed ID: 34230200
[TBL] [Abstract][Full Text] [Related]
2. Recommendations for assessing appearance concerns related to plexiform and cutaneous neurofibromas in neurofibromatosis 1 clinical trials.
Merker VL; Thompson HL; Wolters PL; Buono FD; Hingtgen CM; Rosser T; Barton B; Barnett C; Smith T; Haberkamp D; McManus ML; Baldwin A; Moss IP; Röhl C; Martin S
Clin Trials; 2024 Feb; 21(1):6-17. PubMed ID: 38140900
[TBL] [Abstract][Full Text] [Related]
3. NF1 plexiform neurofibroma growth rate by volumetric MRI: relationship to age and body weight.
Dombi E; Solomon J; Gillespie AJ; Fox E; Balis FM; Patronas N; Korf BR; Babovic-Vuksanovic D; Packer RJ; Belasco J; Goldman S; Jakacki R; Kieran M; Steinberg SM; Widemann BC
Neurology; 2007 Feb; 68(9):643-7. PubMed ID: 17215493
[TBL] [Abstract][Full Text] [Related]
4. Current whole-body MRI applications in the neurofibromatoses: NF1, NF2, and schwannomatosis.
Ahlawat S; Fayad LM; Khan MS; Bredella MA; Harris GJ; Evans DG; Farschtschi S; Jacobs MA; Chhabra A; Salamon JM; Wenzel R; Mautner VF; Dombi E; Cai W; Plotkin SR; Blakeley JO; ;
Neurology; 2016 Aug; 87(7 Suppl 1):S31-9. PubMed ID: 27527647
[TBL] [Abstract][Full Text] [Related]
5. Quantitative assessment of whole-body tumor burden in adult patients with neurofibromatosis.
Plotkin SR; Bredella MA; Cai W; Kassarjian A; Harris GJ; Esparza S; Merker VL; Munn LL; Muzikansky A; Askenazi M; Nguyen R; Wenzel R; Mautner VF
PLoS One; 2012; 7(4):e35711. PubMed ID: 22558206
[TBL] [Abstract][Full Text] [Related]
6. Characteristics of children enrolled in treatment trials for NF1-related plexiform neurofibromas.
Kim A; Gillespie A; Dombi E; Goodwin A; Goodspeed W; Fox E; Balis FM; Widemann BC
Neurology; 2009 Oct; 73(16):1273-9. PubMed ID: 19841379
[TBL] [Abstract][Full Text] [Related]
7. [Plexiform cervical neurofibroma: about a case].
Bouimetarhan L; Bellamlih H; En-Nafaa I; Fenni JE; Amil T; Radouane B
Pan Afr Med J; 2018; 30():41. PubMed ID: 30167068
[TBL] [Abstract][Full Text] [Related]
8. Quantitative associations of scalp and body subcutaneous neurofibromas with internal plexiform tumors in neurofibromatosis 1.
Jett K; Nguyen R; Arman D; Birch P; Chohan H; Farschtschi S; Fuensterer C; Kluwe L; Friedman JM; Mautner VF
Am J Med Genet A; 2015 Jul; 167(7):1518-24. PubMed ID: 25900062
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.
Widemann BC; Babovic-Vuksanovic D; Dombi E; Wolters PL; Goldman S; Martin S; Goodwin A; Goodspeed W; Kieran MW; Cohen B; Blaney SM; King A; Solomon J; Patronas N; Balis FM; Fox E; Steinberg SM; Packer RJ
Pediatr Blood Cancer; 2014 Sep; 61(9):1598-602. PubMed ID: 24753394
[TBL] [Abstract][Full Text] [Related]
10. Longitudinal study of neurofibromatosis 1 associated plexiform neurofibromas.
Tucker T; Friedman JM; Friedrich RE; Wenzel R; Fünsterer C; Mautner VF
J Med Genet; 2009 Feb; 46(2):81-5. PubMed ID: 18930997
[TBL] [Abstract][Full Text] [Related]
11. [18F]-Fluorodeoxyglucose positron emission tomography in children with neurofibromatosis type 1 and plexiform neurofibromas: correlation with malignant transformation.
Tsai LL; Drubach L; Fahey F; Irons M; Voss S; Ullrich NJ
J Neurooncol; 2012 Jul; 108(3):469-75. PubMed ID: 22407214
[TBL] [Abstract][Full Text] [Related]
12. Plexiform neurofibromas.
Korf BR
Am J Med Genet; 1999 Mar; 89(1):31-7. PubMed ID: 10469434
[TBL] [Abstract][Full Text] [Related]
13. Selumetinib in children with neurofibromatosis type 1 and asymptomatic inoperable plexiform neurofibroma at risk for developing tumor-related morbidity.
Gross AM; Glassberg B; Wolters PL; Dombi E; Baldwin A; Fisher MJ; Kim A; Bornhorst M; Weiss BD; Blakeley JO; Whitcomb P; Paul SM; Steinberg SM; Venzon DJ; Martin S; Carbonell A; Heisey K; Therrien J; Kapustina O; Dufek A; Derdak J; Smith MA; Widemann BC
Neuro Oncol; 2022 Nov; 24(11):1978-1988. PubMed ID: 35467749
[TBL] [Abstract][Full Text] [Related]
14. Management of neurofibromatosis type 1-associated plexiform neurofibromas.
Fisher MJ; Blakeley JO; Weiss BD; Dombi E; Ahlawat S; Akshintala S; Belzberg AJ; Bornhorst M; Bredella MA; Cai W; Ferner RE; Gross AM; Harris GJ; Listernick R; Ly I; Martin S; Mautner VF; Salamon JM; Salerno KE; Spinner RJ; Staedtke V; Ullrich NJ; Upadhyaya M; Wolters PL; Yohay K; Widemann BC
Neuro Oncol; 2022 Nov; 24(11):1827-1844. PubMed ID: 35657359
[TBL] [Abstract][Full Text] [Related]
15. Head circumference and anthropometric changes and their relation to plexiform and skin neurofibromas in sporadic and familial neurofibromatosis 1 Brazilian adults: a cross-sectional study.
Basto DL; de Souza Vieira G; Andrade-Losso RM; Almeida PN; Riccardi VM; Rozza-de-Menezes RE; Cunha KS
Orphanet J Rare Dis; 2022 Sep; 17(1):341. PubMed ID: 36064430
[TBL] [Abstract][Full Text] [Related]
16. Response of NF1-related plexiform neurofibroma to high-dose carboplatin.
Hummel T; Anyane-Yeboa A; Mo J; Towbin A; Weiss B
Pediatr Blood Cancer; 2011 Mar; 56(3):488-90. PubMed ID: 21225936
[TBL] [Abstract][Full Text] [Related]
17. The effect of pregnancy on growth-dynamics of neurofibromas in Neurofibromatosis type 1.
Well L; Jaeger A; Kehrer-Sawatzki H; Farschtschi S; Avanesov M; Sauer M; de Sousa MT; Bannas P; Derlin T; Adam G; Mautner VF; Salamon JM
PLoS One; 2020; 15(4):e0232031. PubMed ID: 32343738
[TBL] [Abstract][Full Text] [Related]
18. Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.
Fisher MJ; Shih CS; Rhodes SD; Armstrong AE; Wolters PL; Dombi E; Zhang C; Angus SP; Johnson GL; Packer RJ; Allen JC; Ullrich NJ; Goldman S; Gutmann DH; Plotkin SR; Rosser T; Robertson KA; Widemann BC; Smith AE; Bessler WK; He Y; Park SJ; Mund JA; Jiang L; Bijangi-Vishehsaraei K; Robinson CT; Cutter GR; Korf BR; ; Blakeley JO; Clapp DW
Nat Med; 2021 Jan; 27(1):165-173. PubMed ID: 33442015
[TBL] [Abstract][Full Text] [Related]
19. Visual outcomes in children with neurofibromatosis type 1 and orbitotemporal plexiform neurofibromas.
Avery RA; Dombi E; Hutcheson KA; Acosta MT; Baldwin AM; Madigan WP; Gillespie A; Fitzgibbon EJ; Packer RJ; Widemann BC
Am J Ophthalmol; 2013 Jun; 155(6):1089-1094.e1. PubMed ID: 23453281
[TBL] [Abstract][Full Text] [Related]
20. 18-fluorodeoxyglucose-positron emission tomography (FDG-PET) evaluation of nodular lesions in patients with Neurofibromatosis type 1 and plexiform neurofibromas (PN) or malignant peripheral nerve sheath tumors (MPNST).
Meany H; Dombi E; Reynolds J; Whatley M; Kurwa A; Tsokos M; Salzer W; Gillespie A; Baldwin A; Derdak J; Widemann B
Pediatr Blood Cancer; 2013 Jan; 60(1):59-64. PubMed ID: 22645095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
